Search Results

You are looking at 1 - 10 of 363 items for :

  • "neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia

William Alegria, Bernard L. Marini, Kevin Sellery Gregg, Dale Lee Bixby, Anthony Perissinotti, and Jerod Nagel

Background The optimal duration of antibiotic therapy for patients with febrile neutropenia (FN) remains unknown. The Infectious Diseases Society of America recommends broad-spectrum intravenous antibiotic therapy until neutrophil count recovery

Full access

A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group

Gary H. Lyman and Marek S. Poniewierski

Neutropenia and its complications represent the major dose-limiting toxicities associated with systemic cancer chemotherapy and is associated with considerable morbidity, mortality, and cost. 1 Neutropenic events may result in dose reductions or

Full access

BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High–Neutropenia Risk Chemotherapy

Pamala A. Pawloski, Cara L. McDermott, James H. Marshall, Vanita Pindolia, Catherine M. Lockhart, Catherine A. Panozzo, Jeffrey S. Brown, and Bernadette Eichelberger

Background Prophylaxis with the recombinant human granulocyte colony-stimulating factors (G-CSFs) filgrastim and pegfilgrastim prevents chemotherapy-induced neutropenia; reduces febrile neutropenia (FN) risk and infection-related and early

Full access

Real-World Impact of a Decision Support Tool on Colony-Stimulating Factor Use and Chemotherapy-Induced Febrile Neutropenia Among Patients With Breast Cancer

Abiy Agiro, Andrea DeVries, Jennifer Malin, and Michael J. Fisch

Factors recommend febrile neutropenia (FN) prophylaxis using a colony-stimulating factor (CSF) when risk, based on the chemotherapy regimen and patient risk factors, is “high” (>20%). 7 CSF prophylaxis may also be considered based on patient risk factors

Full access

Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy

Douglas W. Blayney, Nicole M. Kuderer, Alice Kate Cummings Joyner, John Jarvis, Dominic Nunag, Jasmine Wells, Lan Huang, Ramon Monhanlal, and Gary H. Lyman

Background Patients with breast cancer treated with myelosuppressive chemotherapy are at an increased risk of developing febrile neutropenia (FN), a medical emergency characterized by the occurrence of fever during a period of significant

Full access

Antibacterial Prophylaxis in Patients with Neutropenia

Brahm H. Segal and Alison G. Freifeld

-induced neutropenia: risks, consequences, and new directions for its management . Cancer 2004 ; 100 : 228 – 237 . 2. Lyman GH Morrison VA Dale DC . Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP

Full access

Treatment Strategies for Myeloid Growth Factors and Intravenous Iron: When, What, and How?

Jeffrey Crawford and George M. Rodgers

Chemotherapy-induced neutropenia is hazardous for 2 reasons: it produces febrile neutropenia (FN), which may result in life-threatening infections and prolonged hospitalizations, and it can necessitate chemotherapy dose reductions and delays

Full access

Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical Trials

David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman

R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med 1991 ; 325 : 164 – 170 . 11 Trillet-Lenoir V Green J Manegold C

Full access

Myeloid Growth Factors

Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt, and Michael K. Wong

: reporting practices from randomized clinical trials . J Natl Compr Canc Netw 2003 ; 1 : 440 – 454 . 2 Dale DC . Colony-stimulating factors for the management of neutropenia in cancer patients . Drugs 2002 ; 62 ( Suppl 1 ): 1 – 15 . 3

Full access

Management of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value

Michaela A. Dinan, Bradford R. Hirsch, and Gary H. Lyman

the future by more sophisticated personalization of care and more selective administration of interventions to those who stand to benefit most. Use Case: Colony-Stimulating Factors for the Prevention of Febrile Neutropenia Febrile neutropenia